These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 35238940)

  • 1. Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial.
    EMPA-KIDNEY Collaborative Group
    Nephrol Dial Transplant; 2022 Jun; 37(7):1317-1329. PubMed ID: 35238940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics.
    Wheeler DC; Stefansson BV; Batiushin M; Bilchenko O; Cherney DZI; Chertow GM; Douthat W; Dwyer JP; Escudero E; Pecoits-Filho R; Furuland H; Górriz JL; Greene T; Haller H; Hou FF; Kang SW; Isidto R; Khullar D; Mark PB; McMurray JJV; Kashihara N; Nowicki M; Persson F; Correa-Rotter R; Rossing P; Toto RD; Umanath K; Van Bui P; Wittmann I; Lindberg M; Sjöström CD; Langkilde AM; Heerspink HJL
    Nephrol Dial Transplant; 2020 Oct; 35(10):1700-1711. PubMed ID: 32862232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial.
    EMPA-KIDNEY Collaborative Group
    Lancet Diabetes Endocrinol; 2024 Jan; 12(1):39-50. PubMed ID: 38061371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Empagliflozin and Cardiovascular and Kidney Outcomes across KDIGO Risk Categories:
    Levin A; Perkovic V; Wheeler DC; Hantel S; George JT; von Eynatten M; Koitka-Weber A; Wanner C;
    Clin J Am Soc Nephrol; 2020 Oct; 15(10):1433-1444. PubMed ID: 32994159
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
    Zelniker TA; Raz I; Mosenzon O; Dwyer JP; Heerspink HHJL; Cahn A; Goodrich EL; Im K; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Gause-Nilsson I; Langkilde AM; Sabatine MS; Wiviott SD
    JAMA Cardiol; 2021 Jul; 6(7):801-810. PubMed ID: 33851953
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial.
    Heerspink HJL; Stefansson BV; Chertow GM; Correa-Rotter R; Greene T; Hou FF; Lindberg M; McMurray J; Rossing P; Toto R; Langkilde AM; Wheeler DC;
    Nephrol Dial Transplant; 2020 Feb; 35(2):274-282. PubMed ID: 32030417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin and Clinical Outcomes in Patients With Type 2 Diabetes Mellitus, Established Cardiovascular Disease, and Chronic Kidney Disease.
    Wanner C; Lachin JM; Inzucchi SE; Fitchett D; Mattheus M; George J; Woerle HJ; Broedl UC; von Eynatten M; Zinman B;
    Circulation; 2018 Jan; 137(2):119-129. PubMed ID: 28904068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial.
    EMPA-KIDNEY Collaborative Group
    Lancet Diabetes Endocrinol; 2024 Jan; 12(1):51-60. PubMed ID: 38061372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: Results from the EMPA-REG OUTCOME
    Kadowaki T; Nangaku M; Hantel S; Okamura T; von Eynatten M; Wanner C; Koitka-Weber A
    J Diabetes Investig; 2019 May; 10(3):760-770. PubMed ID: 30412655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Heerspink HJL; Jongs N; Chertow GM; Langkilde AM; McMurray JJV; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Greene T;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):743-754. PubMed ID: 34619108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of empagliflozin in patients with chronic kidney disease from Japan: exploratory analyses from EMPA-KIDNEY.
    Nangaku M; Herrington WG; Goto S; Maruyama S; Kashihara N; Ueki K; Wada J; Watada H; Nakashima E; Lee R; Massey D; Mayne KJ; Tomita A; Haynes R; Hauske SJ; Kadowaki T
    Clin Exp Nephrol; 2024 Jun; 28(6):588-595. PubMed ID: 38643286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Empagliflozin in Type 2 Diabetes With and Without Chronic Kidney Disease and Nondiabetic Chronic Kidney Disease: Protocol for 3 Crossover Randomized Controlled Trials (SiRENA Project).
    Nielsen SF; Duus CL; Buus NH; Bech JN; Mose FH
    JMIR Res Protoc; 2024 May; 13():e56067. PubMed ID: 38680116
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Empagliflozin and Kidney Function Decline in Patients with Type 2 Diabetes: A Slope Analysis from the EMPA-REG OUTCOME Trial.
    Wanner C; Heerspink HJL; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; Hantel S; Woerle HJ; Broedl UC; von Eynatten M; Groop PH;
    J Am Soc Nephrol; 2018 Nov; 29(11):2755-2769. PubMed ID: 30314978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Empagliflozin in Patients with Chronic Kidney Disease.
    ; Herrington WG; Staplin N; Wanner C; Green JB; Hauske SJ; Emberson JR; Preiss D; Judge P; Mayne KJ; Ng SYA; Sammons E; Zhu D; Hill M; Stevens W; Wallendszus K; Brenner S; Cheung AK; Liu ZH; Li J; Hooi LS; Liu W; Kadowaki T; Nangaku M; Levin A; Cherney D; Maggioni AP; Pontremoli R; Deo R; Goto S; Rossello X; Tuttle KR; Steubl D; Petrini M; Massey D; Eilbracht J; Brueckmann M; Landray MJ; Baigent C; Haynes R
    N Engl J Med; 2023 Jan; 388(2):117-127. PubMed ID: 36331190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
    Cherney DZI; Zinman B; Inzucchi SE; Koitka-Weber A; Mattheus M; von Eynatten M; Wanner C
    Lancet Diabetes Endocrinol; 2017 Aug; 5(8):610-621. PubMed ID: 28666775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in patients with type 2 diabetes and Stages 3b-4 chronic kidney disease.
    Dekkers CCJ; Wheeler DC; Sjöström CD; Stefansson BV; Cain V; Heerspink HJL
    Nephrol Dial Transplant; 2018 Nov; 33(11):2005-2011. PubMed ID: 29370424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis from the EMPA-REG OUTCOME
    Mayer GJ; Wanner C; Weir MR; Inzucchi SE; Koitka-Weber A; Hantel S; von Eynatten M; Zinman B; Cherney DZI
    Kidney Int; 2019 Aug; 96(2):489-504. PubMed ID: 31142441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA
    Rosenstock J; Perkovic V; Alexander JH; Cooper ME; Marx N; Pencina MJ; Toto RD; Wanner C; Zinman B; Baanstra D; Pfarr E; Mattheus M; Broedl UC; Woerle HJ; George JT; von Eynatten M; McGuire DK;
    Cardiovasc Diabetol; 2018 Mar; 17(1):39. PubMed ID: 29540217
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.